Famn Pharma Private Limited - pharma in New Delhi, Delhi, India. FY 2026 financials & compliance.
CIN U33110DL2019PTC353197 Incorporated 30 July 2019 ROC Delhi HQ New Delhi, Delhi, India
Active Private Limited Company pharma
Revenue · FY 2026
₹13.3 Cr
▲ 24% YoY
Net profit · FY 2026
₹6.71 Lakh
Net margin 0.5%
EBITDA · FY 2026
₹23.69 Lakh
EBITDA margin 1.8%
Authorised capital
₹1 Lakh
Registered with MCA
Paid-up capital
₹1 Lakh
Issued & subscribed
Open charges
₹1.35 Cr
Secured borrowings
Company age
7 yrs
Est. 2019
Directors on board
2
As per MCA filings

About Famn Pharma Private Limited

Data last updated:

Famn Pharma Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 30 July 2019 and has been in existence for over 7 years.

The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U33110DL2019PTC353197. Its GSTIN is 07AADCF8116C1ZZ (Delhi). The company holds 2 GST registrations, all of them active.

The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Neelam Girishkumar Singh and Sunjeet Kumar Singh.

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Shop No.145 First Floor Vardhaman Crown Mall Plot No.2 Sector – 1, 9 Dwarka, New Delhi, Delhi, India – 110078.

As per the financials filed for FY 2026, the company reported a revenue of ₹13.3 Cr, a growth of 24% compared to the previous year. For the same year it recorded a net profit of ₹6.71 Lakh (net margin 0.5%) and EBITDA of ₹23.69 Lakh (EBITDA margin 1.8%). Revenue has grown at a compounded annual rate (CAGR) of 11% over three years and 43% over five years.

The company is associated with 1 brand: Famn Pharma. As per MCA filings, the company has open charges of ₹1.35 Cr on record.

For more details, the company can be reached via its website famnpharmaceuticals.co.in.

Company details

CIN U33110DL2019PTC353197
Registration Number 353197
Incorporation Date 30 July 2019
ROC Delhi
Listing Status Unlisted
Company Status Active

Contact details

Famn Pharma Private Limited's registered office is in New Delhi, Delhi. Its website is famnpharmaceuticals.co.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    Shop No.145 First Floor Vardhaman Crown Mall Plot No.2 Sector – 1, 9 Dwarka, New Delhi, Delhi, India – 110078
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Famn Pharma Private Limited, buy the company report.

Comprehensive company report
Famn Pharma Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Famn Pharma operates one associated brand: Famn Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Manufactures and supplies pharmaceutical products including tablets and injections.famnpharma.com

Business activity

The main business activity of Famn Pharma is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing21Manufacture of basic pharmaceutical products and pharmaceutical preparations

To see the full business activity and turnover split of Famn Pharma Private Limited, buy the company report.

Financials of Famn Pharma Private Limited

FY 2026 filings available

Famn Pharma Private Limited reported revenue of ₹13.3 Cr (up 24% YoY) for FY 2026.

Revenue · FY 2026
₹13.3 Cr ▲ 24%
Net profit · FY 2026
₹6.71 Lakh margin 0.5%
EBITDA · FY 2026
₹23.69 Lakh margin 1.8%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 24%
3 years · compounded
▼ 11%
5 years · compounded
▲ 43%
EBITDA CAGR growth
1 year
▲ 8%
3 years · compounded
▼ 6%

Revenue has grown at a compounded annual rate (CAGR) of 43% over five years, including 24% growth in the latest year. EBITDA rose 8% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue₹13.3 Cr
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹23.69 Lakh
Profit Before Tax
Tax Expense
Net Profit (PAT)₹6.71 Lakh
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Profitability
EBITDA Margin1.8%
Net Profit Margin0.5%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Famn Pharma Private Limited, buy the company report.

Board of directors of Famn Pharma Private Limited

Famn Pharma has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Neelam Girishkumar SinghDirector30 Jul 20197 Years 3 MonthsCurrent
Sunjeet Kumar SinghDirector11 Feb 20233 Years 9 MonthsCurrent

Auditor

Famn Pharma Private Limited is audited by YOGESH K. DAVE & CO. for the financial year 2026.

Auditor firmFinancial yearFirm registration number
YOGESH K. DAVE & CO.FY 2026111756W

Shareholding

The shareholding of Famn Pharma Private Limited is on record for 5 financial years, the latest being FY 2026, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2026FY 2025FY 2024FY 2023FY 2022
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Famn Pharma Private Limited, buy the company report.

Charges & borrowings

Open charges
₹1.35 Cr
Satisfied charges
None
Breakdown by lending institutions
Axis Bank Limited₹1.35 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
10 Jun 2025101109196Axis Bank Limited₹1.35 CrOpen

Total charge records: 1 View all charges

MSME payment delays

No delayed payments to MSME suppliers are on our record for Famn Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Famn Pharma has 2 GST registrations: 2 active.

Total GSTINs
2
Active
2
GSTINStateStatusRegistered on
07AADCF8116C1ZZDelhiActive08 Aug 2019
06AADCF8116C1Z1HaryanaActive01 Jun 2021

To see the full GST registrations and return filing status of Famn Pharma Private Limited, buy the company report.

Recent activity

Famn Pharma Private Limited has 4 board changes on record since 2019: 2 appointments and 2 cessations. The latest: Devendra Girishbhai Singh ceased to be Additional Director on 22 Jun 2024.

Filing
Famn Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Delhi.
AGM
Famn Pharma Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge with Axis Bank Limited amounted to Rs. 135.00 Lakh with Charge ID 101109196 was registered on 10 Jun 2025.
Ceased
Devendra Girishbhai Singh ceased to be Additional Director.
Appointed
Sunjeet Kumar Singh was appointed as Director.
Ceased
Renu Raghav ceased to be Director.
Appointed
Neelam Girishkumar Singh was appointed as Director.
Incorporation
30 Jul 2019
Famn Pharma Private Limited was registered on 30 Jul 2019 with Roc Delhi & aged 7 years 3 months as per MCA records.

Frequently asked questions

Famn Pharma is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 30 July 2019 (7+ years old) and is registered under CIN U33110DL2019PTC353197.

Famn Pharma has 2 current directors:

The latest financial statements of Famn Pharma on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2020 are in the company report.

The GSTIN of Famn Pharma is 07AADCF8116C1ZZ, registered in Delhi. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 06AADCF8116C1Z1 (Haryana).

The CIN (Corporate Identification Number) of Famn Pharma is U33110DL2019PTC353197. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Famn Pharma was incorporated on 30 July 2019, making it 7+ years old. It is registered with the Registrar of Companies, Delhi.

Devendra Girishbhai Singh ceased to be Additional Director on 22 Jun 2024. Sunjeet Kumar Singh was appointed as Director on 11 Feb 2023. Renu Raghav ceased to be Director on 06 Feb 2021. Famn Pharma has 4 board changes on record in total.

Famn Pharma can be reached through the website famnpharmaceuticals.co.in. Its registered office is in New Delhi, Delhi, India.

The registered office of Famn Pharma is at Shop No.145 First Floor Vardhaman Crown Mall Plot No.2 Sector – 1, 9 Dwarka, New Delhi, Delhi, India – 110078.

Famn Pharma operates in the pharma industry, in the drug formulation and development segment.